Preeclampsia; short and long-term consequences for mother and neonate

Early Human Development

Volumn 102, Issue , 2016, Pages 47-50

  Bokslag, Anouk ^a   van Weissenbruch, Mirjam ^a   Mol, Ben Willem ^b,c   de Groot, Christianne J M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Fetal outcome; Maternal health; Preeclampsia

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADVERSE OUTCOME; ANTIHYPERTENSIVE THERAPY; FEMALE; HUMAN; MATERNAL HYPERTENSION; MOTHER; NEWBORN; PREECLAMPSIA; PREGNANCY OUTCOME; PROGENY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CHILD DEVELOPMENT; MATERNAL WELFARE; PREGNANCY; PRENATAL EXPOSURE;

CHILD DEVELOPMENT; FEMALE; HUMANS; INFANT, NEWBORN; MATERNAL HEALTH; PRE-ECLAMPSIA; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84993960837     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2016.09.007     Document Type: Review

References (41)

1. [1] Ananth, C.V., Keyes, K.M., Wapner, R.J., Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ, 347, 2013, f6564.
2. [2] Tranquilli, A.L., Dekker, G., Magee, L., Roberts, J., Sibai, B.M., Steyn, W., et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 4:2 (Apr 2014), 97–104.
3. [3] Lisonkova, S., Sabr, Y., Mayer, C., Young, C., Skoll, A., Joseph, K.S., Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet. Gynecol. 124:4 (Oct 2014), 771–781.
4. [4] Powe, C.E., Levine, R.J., Karumanchi, S.A., Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123:24 (Jun 21 2011), 2856–2869.
5. [5] Mutter, W.P., Karumanchi, S.A., Molecular mechanisms of preeclampsia. Microvasc. Res. 75:1 (Jan 2008), 1–8.
6. [6] Phipps, E., Prasanna, D., Brima, W., Jim, B., Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin. J. Am. Soc. Nephrol. 11:6 (Jun 6 2016), 1102–1113.
7. [7] Duckitt, K., Harrington, D., Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ, 330(7491), Mar 12 2005, 565.
8. [8] Broekhuijsen, K., van Baaren, G.J., van Pampus, M.G., Ganzevoort, W., Sikkema, J.M., Woiski, M.D., et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. Lancet 385:9986 (Jun 20 2015), 2492–2501.
9. [9] Koopmans, C.M., Bijlenga, D., Groen, H., Vijgen, S.M., Aarnoudse, J.G., Bekedam, D.J., et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 374:9694 (Sep 19 2009), 979–988.
10. [10] Odegard, R.A., Vatten, L.J., Nilsen, S.T., Salvesen, K.A., Austgulen, R., Preeclampsia and fetal growth. Obstet. Gynecol. 96:6 (Dec 2000), 950–955.
11. [11] Harmon, Q.E., Huang, L., Umbach, D.M., Klungsoyr, K., Engel, S.M., Magnus, P., et al. Risk of fetal death with preeclampsia. Obstet. Gynecol. 125:3 (Mar 2015), 628–635.
12. [12] Davies, E.L., Bell, J.S., Bhattacharya, S., Preeclampsia and preterm delivery: a population-based case–control study. Hypertens. Pregnancy 20 (Jun 2016), 1–10.
13. [13] Goldenberg, R.L., Culhane, J.F., Iams, J.D., Romero, R., Epidemiology and causes of preterm birth. Lancet 371:9606 (Jan 5 2008), 75–84.
14. [14] Saigal, S., Doyle, L.W., An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 371:9608 (Jan 19 2008), 261–269.
15. [15] Barron, W.M., Lindheimer, M.D., Hypertension. Medical Disorders During Pregnancy, 3rd ed., 2000, Mosby, 1–38.
16. [16] Schutte, J.M., Steegers, E.A., Schuitemaker, N.W., Santema, J.G., de BK, Pel, M., et al. Rise in maternal mortality in the Netherlands. BJOG 117:4 (Mar 2010), 399–406.
17. [17] Magee, L.A., Namouz-Haddad, S., Cao, V., Koren, G., von DP, Labetalol for hypertension in pregnancy. Expert Opin. Drug Saf. 14:3 (Mar 2015), 453–461.
18. [18] von Dadelszen, P., Ornstein, M.P., Bull, S.B., Logan, A.G., Koren, G., Magee, L.A., Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 355:9198 (Jan 8 2000), 87–92.
19. [19] von Dadelszen, P., Magee, L.A., Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J. Obstet. Gynaecol. Can. 24:12 (Dec 2002), 941–945.
20. [20] Duley, L., Meher, S., Jones, L., Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst. Rev., 7, 2013, CD001449.
21. [21] Heida, K.Y., Zeeman, G.G., Van Veen, T.R., Hulzebos, C.V., Neonatal side effects of maternal labetalol treatment in severe preeclampsia. Early Hum. Dev. 88:7 (Jul 2012), 503–507.
22. [22] Pasker-de Jong, P.C., Zielhuis, G.A., van Gelder, M.M., Pellegrino, A., Gabreels, F.J., Eskes, T.K., Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study. BJOG 117:9 (Aug 2010), 1080–1086.
23. [23] Nooij, L.S., Visser, S., Meuleman, T., Vos, P., Roelofs, R., de Groot, C.J., The optimal treatment of severe hypertension in pregnancy: update of the role of nicardipine. Curr. Pharm. Biotechnol. 15:1 (2014), 64–69.
24. [24] Raheem, I.A., Saaid, R., Omar, S.Z., Tan, P.C., Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG 119:1 (Jan 2012), 78–85.
25. [25] Vadhera, R.B., Simon, M., Hypertensive emergencies in pregnancy. Clin. Obstet. Gynecol. 57:4 (Dec 2014), 797–805.
26. [26] Doyle, L.W., Crowther, C.A., Middleton, P., Marret, S., Rouse, D., Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst. Rev., 1, 2009, CD004661.
27. [27] Rouse, D.J., Hirtz, D.G., Thom, E., Varner, M.W., Spong, C.Y., Mercer, B.M., et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N. Engl. J. Med. 359:9 (Aug 28 2008), 895–905.
28. [28] Duley, L., Gulmezoglu, A.M., Henderson-Smart, D.J., Chou, D., Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst. Rev., 11, 2010, CD000025.
29. [29] Oddie, S., Tuffnell, D.J., McGuire, W., Antenatal magnesium sulfate: neuro-protection for preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. 100:6 (Nov 2015), F553–F557.
30. [30] Pinheiro, T.V., Brunetto, S., Ramos, J.G., Bernardi, J.R., Goldani, M.Z., Hypertensive disorders during pregnancy and health outcomes in the offspring: a systematic review. J. Dev. Orig. Health Dis. 7:4 (Aug 2016), 391–407.
31. [31] Ehr von, J., von Versen-Hoynck, F., Implications of maternal conditions and pregnancy course on offspring's medical problems in adult life. Arch. Gynecol. Obstet., 13, Aug 2016.
32. [32] Kajantie, E., Eriksson, J.G., Osmond, C., Thornburg, K., Barker, D.J., Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke 40:4 (Apr 2009), 1176–1180.
33. [33] Cheng, S.W., Chou, H.C., Tsou, K.I., Fang, L.J., Tsao, P.N., Delivery before 32 weeks of gestation for maternal pre-eclampsia: neonatal outcome and 2-year developmental outcome. Early Hum. Dev. 76:1 (Jan 2004), 39–46.
34. [34] van Wassenaer, A.G., Westera, J., van Schie, P.E., Houtzager, B.A., Cranendonk, A., de GL, et al. Outcome at 4.5 years of children born after expectant management of early-onset hypertensive disorders of pregnancy. Am. J. Obstet. Gynecol. 204:6 (Jun 2011), 510–519.
35. [35] Lykke, J.A., Langhoff-Roos, J., Sibai, B.M., Funai, E.F., Triche, E.W., Paidas, M.J., Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 53:6 (Jun 2009), 944–951.
36. [36] Bellamy, L., Casas, J.P., Hingorani, A.D., Williams, D.J., Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ, 335(7627), Nov 10 2007, 974.
37. [37] Hermes, W., Franx, A., van Pampus, M.G., Bloemenkamp, K.W., Bots, M.L., van der Post, J.A., et al. Cardiovascular risk factors in women who had hypertensive disorders late in pregnancy: a cohort study. Am. J. Obstet. Gynecol. 208:6 (Jun 2013), 474–478.
38. [38] Veerbeek, J.H., Hermes, W., Breimer, A.Y., van Rijn, B.B., Koenen, S.V., Mol, B.W., et al. Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension. Hypertension 65:3 (Mar 2015), 600–606.
39. [39] Mongraw-Chaffin, M.L., Cirillo, P.M., Cohn, B.A., Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension 56:1 (Jul 2010), 166–171.
40. [40] Heida, K.Y., Franx, A., van Rijn, B.B., Eijkemans, M.J., Boer, J.M., Verschuren, M.W., et al. Earlier age of onset of chronic hypertension and type 2 diabetes mellitus after a hypertensive disorder of pregnancy or gestational diabetes mellitus. Hypertension 66:6 (Dec 2015), 1116–1122.
41. [41] Auger, N., Fraser, W.D., Schnitzer, M., Leduc, L., Healy-Profitos, J., Paradis, G., Recurrent pre-eclampsia and subsequent cardiovascular risk. Heart, Aug 16 2016.